Advertisement
Cambium Bio Limited

Cambium Bio Limited (CMB.AX) Stock Competitors & Peer Comparison

See (CMB.AX) competitors and their performances in Stock Market.

CMB.AXASX
HealthcareBiotechnology
$0.43
$0.005(1.14%)
Australian Market opens in 50h 7m
Advertisement

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
CMB.AXA$0.43+2.38%9.9M-6.14-A$0.07N/A
CSL.AXA$114.74-0.56%55B12.34A$9.30+3.71%
TLX.AXA$16.58+2.54%5.6B-598.34-A$0.03N/A
MSB.AXA$1.96+0.51%2.5B-13.15-A$0.15N/A
NEU.AXA$17.75+6.93%2.3B75.56A$0.23N/A
PYC.AXA$1.69+2.42%982.4M-36.95-A$0.05N/A
OPT.AXA$0.60+0.00%820.8M6.14A$0.10N/A
CUV.AXA$10.28-0.68%518.2M15.96A$0.64+0.49%
RAC.AXA$2.22-0.45%435.3M-107.25-A$0.02N/A
SPL.AXA$0.70+0.72%294.6M111.11A$0.01N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

CMB.AX vs CSL.AX Comparison July 2026

CMB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CMB.AX stands at 9.9M. In comparison, CSL.AX has a market cap of 55B. Regarding current trading prices, CMB.AX is priced at A$0.43, while CSL.AX trades at A$114.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CMB.AX currently has a P/E ratio of -6.14, whereas CSL.AX's P/E ratio is 12.34. In terms of profitability, CMB.AX's ROE is -2.19%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, CMB.AX is less volatile compared to CSL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CMB.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions